Log in
Enquire now
‌

US Patent 12109238 Chimeric antigen receptor-modified NK-92 cells

Patent 12109238 was granted and assigned to ImmunityBio on October, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
ImmunityBio
ImmunityBio
0
Date Filed
July 13, 2022
0
Date of Patent
October 8, 2024
0
Patent Applicant
ImmunityBio
ImmunityBio
0
Patent Application Number
17812264
0
Patent Citations
‌
US Patent 9181322 Genetically modified human natural killer cell lines
0
‌
US Patent 10138462 Natural killer cell lines and methods of use
0
‌
US Patent 10738279 Modified NK-92 cells for treating cancer
0
‌
US Patent 10765701 Elimination of CD19-positive lymphoid malignancies by CD19-CAR expressing NK cells
0
‌
US Patent 8034332 Interleukin-secreting natural killer cell lines and methods of use
0
‌
US Patent 7618817 Genetically modified human natural killer cell lines
0
‌
US Patent 8313943 Genetically modified human natural killer cell lines
0
‌
US Patent 9150636 Genetically modified human natural killer cell lines
0
‌
US Patent 7098008 Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
0
Patent Inventor Names
Laurent H. Boissel
0
Hans G. Klingemann
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
12109238
0
Patent Primary Examiner
‌
Amy E Juedes
0
CPC Code
‌
C12N 5/0646
0
‌
C07K 16/32
0
‌
A61K 35/17
0
‌
A61K 35/28
0
‌
A61K 39/3955
0
‌
A61K 45/06
0
‌
A61P 35/00
0
‌
C07K 14/70517
0
‌
C07K 14/70521
0
‌
C07K 14/70535
0
•••

Find more entities like US Patent 12109238 Chimeric antigen receptor-modified NK-92 cells

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.